bioRxiv Science⌕ Search

Biology subjects

Fonseka, P.

Publications and source records attributed to Fonseka, P..

2 recordsLinked to original sources

Apoptotic bodies from patients with Sjogren's disease drive atypical memory B cell and macrophage activation and autoantibody production

The impaired clearance of apoptotic cells has long been associated with systemic autoimmune diseases like Sjogrens disease (SjD), which is characterised by autoantibodies targeting antigens on apoptotic cells. However, most studies analysing human samples have used patient-derived phagocytes and in vitro generated apoptotic cells, which do not reflect the heterogeneity of patient-derived apoptotic bodies (ApoBDs). Here, we molecularly and functionally compare ApoBDs derived from patients with SjD and healthy donors. ApoBDs were increased in the circulation in SjD and induced atypical memory B cell expansion, which was attenuated by blocking B cell receptor (BCR) and Toll-like receptors (TLR) 7-9 signalling. Co-cultures of ApoBDs and B cells drove autoantibody production. Macrophages engulfing SjD ApoBDs had a distinct inflammatory profile compared to macrophages engulfing healthy control ApoBDs. These findings define patient-derived ApoBDs as immunostimulatory substrates capable of driving innate and adaptive immune responses consistent with the pathogenic features observed in SjD, hence opening a new avenue of diagnostic and therapeutic development.

immunology↗

Sulfisoxazole does not inhibit the secretion of small extracellular vesicles

Recently, the study by Im et al. focused on blocking the release of extracellular vesicles (EVs) by cancer cells, as a strategy to block metastasis, by deploying a drug repurposing screen. Upon screening the library of FDA approved drugs in breast cancer cells in vitro, the authors reported the ability of the antibiotic Sulfisoxazole (SFX) in inhibiting EV biogenesis and secretion. SFX was also effective in reducing breast primary tumor burden and blocking metastasis in immunocompromised and immunocompetent mouse models. As we seek a compound to block EV biogenesis and secretion in our current in vivo studies, we intended to use SFX and hence performed in vitro characterization as the first step. However, treatment of two cancer cells with SFX did not reduce the amount of EVs as reported by the authors.

cancer biology↗